Skip to main content
. 2016 Apr 2;15:56. doi: 10.1186/s12933-016-0365-x

Fig. 1.

Fig. 1

Flowchart of subject selection. LHDB longitudinal cohort of diabetes patients, DM diabetes mellitus, ACEi angiotensin converting enzyme inhibitors, ARB angiotensin receptor blockers, ESRD end stage renal disease, MACE major adverse cardiovascular events